Three Hot Technology Stocks: Cloudflare, Microchip, and TSM
After trading at around $100 in the last month, Cloudflare (NET) closed at $132.34. The tech firm posted first-quarter revenue growth and issued its outlook for Q2 and the full year.Cloudflare’s revenue increased by 26.5% year over year to $479.09, earning $0.16 a share. This growth is consistent with that of CrowdStrike (CRWD), ServiceNow (NOW), Snowflake (SNOW), Zscaler (ZS), and Palantir (PLTR). In Q2, CloudFlare forecasts non-GAAP EPS of $0.18 and up to $0.80 for the year.Microchip (MCHP) bottomed at below $40, breaking out in the last few weeks. The company posted Q4/2025 results last week. For Q1, Microchip expects diluted EPS of $0.18 - $0.26, well-above the $0.15 consensus estimate. The company is cutting costs while the industry improves.Taiwan Semiconductor (TSM) is a strong supplier of cutting-edge chips. It unveiled a new A14 process for smartphone AI chip development last month. In addition, TSM reported revenue rising by 48.1% Y/Y to NT$349.57 billion. AI product demand led to higher sales. TSM counts on Apple (AAPL), Nvidia (NVDA), and AMD (AMD) as its customers.Nvidia benefits from TSM’s reliable production. Sales of its graphics chips are barely enough to keep up with the strong demand.TSM is a solid core holding. While its valuation is fair, its growth and profitability continue to increase.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


